6/28/23, 9:54 PM EMPA-HEART2 CardioLink-7 Pathway Feedback Search Clinical Topics Home Studies EMPA HEART2 CardioLink-7 EMPA HEART2 CardioLink-7 Trial question What is the role of empagliflozin in patients without diabetes but with risk of adverse cardiac remodeling? Study design Multi-center Double blinded RCT Population Characteristics of study participants 17.0% female N = 169 83.0% male 169 patients (28 female, 141 male) Inclusion criteria: adult patients, aged 40-80 years, without diabetes but with risk factors for adverse cardiac remodeling Key exclusion criteria: type 1 or 2 diabetes; HbA1c 6.5%, ketoacidosis; systolic BP < 95 mmHg; planned coronary revascularization within the next 6 months or coronary revascularization within the preceding 3 months Interventions N=85 empagliflozin (at a dose of 10 mg/day for 6 months) N=84 placebo (matching placebo for 6 months) Primary outcome Reduction in left ventricular mass indexed to body surface area at 6 months 1.2 g/m 1.2 1.1 0.9 g/m 0.6 g/m 0.3 g/m No significant difference 0.0 g/m https://web.pathway.md/studies/recY6be5pYNOErkQJ 1/2 6/28/23, 9:54 PM EMPA-HEART2 CardioLink-7 Pathway Empagliflozin Placebo No significant difference in reduction in LV mass indexed to BSA at 6 months (1.2 g/m vs. 1.1 g/m ; AD 0.3 g/m , 95% CI -1.5 to 2.1) Secondary outcomes No significant difference in improvement in LVEF at 6 months (1.3% vs. -0.2%; AD 1.5%, 95% CI -0.12 to 3.12) Safety outcomes No significant difference in adverse events. Conclusion In adult patients, aged 40-80 years, without diabetes but with risk factors for adverse cardiac remodeling, empagliflozin was not superior to placebo with respect to reduction in LV mass indexed to BSA at 6 months. Reference Kim A Connelly, C David Mazer, Pankaj Puar et al. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial. Circulation. 2023 Jan 24;147(4):284-295. Open reference URL https://web.pathway.md/studies/recY6be5pYNOErkQJ 2/2